{
  "id": 20662874,
  "title": "Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial",
  "url": "https://urgent.news/2026/11/18/targeting-immune-overactivity-in-down-syndrome-shows-promise-in-phase",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-18T21:40:14.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-11-immune-overactivity-syndrome-phase-clinical.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "In a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with Down syndrome reduced underlying inflammation and was associated with improvements in inflammatory skin conditions, while opening new avenues for research on brain health and…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}